<DOC>
	<DOCNO>NCT01252784</DOCNO>
	<brief_summary>The purpose study evaluate feasibility efficacy reduced-intensity conditioning allogeneic HCT follow prophylactic dose-escalating DLIs patient high risk MDS .</brief_summary>
	<brief_title>Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation</brief_title>
	<detailed_description>Conditioning therapy - Busulfan 3.2 mg/kg/d d-7 -6 - Fludarabine 30 mg/m2 d-7 -2 - ATG 1.5-3.0 mg/kg/d d-3 -1 - Methylpred 2 mg/kg/d d-4 -1 Mobilization harvest - Donor - G-CSF 10 mcg/kg/d s.c. d-3 0 - Harvest PBMCs 0 +1 Infuse G-PBMCs 0 d+1 . - Donor G-PBMC infusion GVHD prophylaxis - Cyclosporine 1.5 mg/kg i.v . q 12 hr begin d-1 changed oral dosing ( twice i.v . dose ) oral intake possible . Tapered begin d+30 d+60 . - Methotrexate 15 mg/m2 i.v . d+2 , 10 mg/m2 i.v . d+4 d+7 Prophylactic dose-escalating DLIs - Begin d+120 least 2 wks IST discontinuation . - No evidence recurrence GVHD CD3+ cell dose increment q 4 wks 4Three dose level</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Patients high risk MDS include chronic myelomonocytic leukemia RAEB1 RAEB2 IPSS Intermediate2 High risk category Chronic myelomonocytic leukemia 2 . Patients appropriate hematopoietic cell donor HLAmatched sibling HLAmatched unrelated donor HLAmismatched familial donor 3.16 year old old â€¢ Presence significant active infection Presence uncontrolled bleed Any coexist major illness organ failure Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>high risk MDS</keyword>
</DOC>